SCHEMBL2934675

SCHEMBL2934675

COC(=O)c1ccc(O)c(NC(=O)OC(C)(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA7 P43166 2/20 0.54
CA9 Q16790 2/20 0.54
CA14 Q9ULX7 2/20 0.54
XDH P47989 1/20 0.54
KDM4E B2RXH2 6/20 0.50
MDH1 P40925 5/20 0.50
MDH2 P40926 5/20 0.50
ALDH1A1 P00352 7/20 0.49
HPGD P15428 5/20 0.49
HSD17B10 Q99714 3/20 0.49
TP53 P04637 2/20 0.49
ALOX15 P16050 2/20 0.49
ALOX12 P18054 2/20 0.49
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3677780 0.88 XDH (0.54) CA12CA1CA2CA7CA9
SCHEMBL16318447 0.88 KDM4E (0.52) CA12CA1CA2CA7CA9
SCHEMBL9865843 0.87 KDM5A (0.50) CA12CA1CA2CA7CA9
SCHEMBL10318265 0.85 ALDH1A1 (0.50) KDM4EALDH1A1HPGDLMNAMAPT
SCHEMBL1390927 0.85 KDM4E (0.48) CA12CA1CA2CA7CA9
SCHEMBL1390928 0.85 KDM4E (0.48) CA12CA1CA2CA7CA9
SCHEMBL4490699 0.84 KDM4E (0.49) CA12CA1CA2CA7CA9
SCHEMBL30816858 0.84 KDM4E (0.49) CA12CA1CA2CA7CA9
SCHEMBL29281561 0.84 KDM4E (0.49) CA12CA1CA2CA7CA9
SCHEMBL31480211 0.84 KDM4E (0.49) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 EP disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
EP-1836163-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN Novartis AG (CH) 2007-09-26 EP disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD CA12 3286/4885CA1 2395/4885CA2 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.